Acuitas CEO Dr Thomas Madden and NanoVation co-founder and president Dr Dominik Witzigmann discuss how LNP engineering is expanding genetic medicine applications to traditionally undruggable targets.
Dominik Witzigmann
Advertisement
Dominik Witzigmann, PhD, is co-founder and president of NanoVation Therapeutics.
Articles by Dominik Witzigmann
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
2
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
3
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
4
Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule
5